Senseonics (NYSE:SENS) said today that it inked a collaboration with TypeZero Technologies and Roche (OTC:RHHBY) Diabetes Care to develop an automated insulin delivery system. The deal is part of an NIH-funded effort to test artificial pancreas systems. The trial is slated to integrate Senseonic’s Eversense glucose monitor, TypeZero’s inControl AP algorithms and Roche’s Accu-Chek Insight insulin pump. […]
Featured
Provention Bio wants to stop Type I diabetes – with a vaccine
Before he co-founded Provention Bio, Ashleigh Palmer worked on inhaled nitric oxide for infants with respiratory failure. After the company was sold for $1.2 billion to a Baxter-led consortium, Palmer noticed there was apprehension about conducting clinical trials with neonates. He was concerned that the inhaled NO assets were slated to fall to the wayside. […]
Pops Diabetes, Children’s Minnesota to test glucometer
Pops Diabetes Care reportedly enrolled the first patient in a clinical trial evaluating its Pops! one glucometer, according to the StarTribune. The Twin Cities-based company is said to be partnering with the Children’s Minnesota healthcare system to study its device in 50 Type I diabetes patients. Get the full story at our sister site, MassDevice.
Samumed wins orphan drug status for inhaled IPF therapy
Samumed said today that the FDA awarded orphan drug status to its inhaled idiopathic pulmonary fibrosis therapy, SMo4646. The IPF therapy is administered using a nebulizer and can be used as a montherapy or in combination with pirfenidone or nintedanib, according to the San Diego-based company. “The FDA’s decision to grant an ODD to SM04646 […]
BioLight’s glaucoma insert succeeds in Phase I/IIa trial
BioLight Life Sciences (TLV:BOLT) touted data today from a Phase I/IIa clinical trial evaluating its Eye-D latanoprost insert. The device successfully lowered intraocular pressure during the study’s 12-week period and had a favorable safety profile, according to the Israel-based company. The latanoprost insert was designed for glaucoma patients who have trouble taking prescribed eye drops […]
J&J touts first-in-human data for HIV vaccine
Johnson & Johnson (NYSE:JNJ) touted first-in-human clinical data today for its investigational HIV vaccine in development by its subsidiary, Janssen Pharmaceutical. The Phase I/IIa trial enrolled 393 healthy volunteers. According to the data, the vaccine was well-tolerated and triggered an HIV antibody response in 100% of participants. “Finding a preventive vaccine has proven to be one […]
Study: Antiretroviral drug-eluting ring safe in breastfeeding mothers
An antiretroviral drug released from an experimental vaginal ring to protect women against HIV is absorbed in low concentrations into breastmilk, according to researchers from the NIH-funded Microbicide Trials Network. The team touted data today from a Phase I trial of the device at the 9th IAS Conference on HIV Sciences in Paris. The dapivirine […]
Healthcare fund Gurnet Point buys Innocoll’s bioresorbable collagen matrix
Healthcare investment fund Gurnet Point said today that it completed its acquisition of pharmaceutical and medical device company Innocoll. According to the deal, Gurnet Point is slated to buy Innocoll for 1.75 per share in cash and up to $4.90 in cash from a contingent value right, in a deal valued up to $209 million. The investment […]
New GSK chief executive to refocus pipeline
GlaxoSmithKline‘s (NYSE:GSK) new chief executive, Emma Walmsley, signaled in April that she plans to cut programs in the company’s pharmaceutical pipeline that aren’t generating enough value, including older antibiotics. “We’ll need to be switching off some areas,” Walmsley said, according to Reuters. She is slated to detail her plans this week when she presents second quarter […]
Novocure brings Optune tech to drug trial for glioblastoma
Novocure (NSDQ:NVCR) said today that it joined a Phase Ib study to evaluate the safety of Celgene‘s (NSDQ:CELG) marizomib and temozolomide in combination with Optune for patients with newly-diagnosed glioblastoma. The trial is the first to assess Optune, the company’s “Tumor Treating Fields” delivery device, in combination with an investigational drug. Celgene and Triphase changed their ongoing […]